Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
14:53
Volodymyr Zelensky: Russia intends to mobilize 300,000 people after the elections for the State Duma
14:29
The nuclear power plant in Paks could return to full capacity by Wednesday, announces the Prime Minister of Hungary.
14:04
A minibus with eight people caught fire while driving on DN 2, in Bacău County. All passengers evacuated themselves without being injured.
13:27
Volodymyr Zelensky: "I believe that, in a war like this, elections in themselves represent an enormous risk"
13:17
The Parliament meets in an extraordinary session, between August 24 and 26, for the PNRR laws.
See more news